A detailed history of Clearstead Advisors, LLC transactions in Dexcom Inc stock. As of the latest transaction made, Clearstead Advisors, LLC holds 1,335 shares of DXCM stock, worth $97,228. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,335
Previous 2,010 33.58%
Holding current value
$97,228
Previous $227,000 60.79%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$64.0 - $116.06 $43,200 - $78,340
-675 Reduced 33.58%
1,335 $89,000
Q2 2024

Aug 09, 2024

BUY
$110.31 - $140.45 $20,297 - $25,842
184 Added 10.08%
2,010 $227,000
Q1 2024

May 14, 2024

BUY
$114.22 - $140.1 $2,170 - $2,661
19 Added 1.05%
1,826 $253,000
Q4 2023

Feb 12, 2024

BUY
$75.49 - $124.16 $3,774 - $6,208
50 Added 2.85%
1,807 $224,000
Q3 2023

Nov 07, 2023

SELL
$86.06 - $137.93 $5,163 - $8,275
-60 Reduced 3.3%
1,757 $163,000
Q2 2023

Aug 07, 2023

BUY
$112.47 - $130.98 $138,900 - $161,760
1,235 Added 212.2%
1,817 $233,000
Q1 2023

May 09, 2023

BUY
$104.0 - $122.92 $4,992 - $5,900
48 Added 8.99%
582 $67,000
Q4 2022

Feb 14, 2023

BUY
$84.98 - $122.67 $4,418 - $6,378
52 Added 10.79%
534 $60,000
Q2 2022

Aug 12, 2022

BUY
$67.99 - $132.89 $25,428 - $49,700
374 Added 346.3%
482 $36,000
Q4 2021

Feb 14, 2022

SELL
$129.87 - $162.82 $7,402 - $9,280
-57 Reduced 34.55%
108 $58,000
Q3 2021

Nov 12, 2021

BUY
$106.71 - $143.18 $6,082 - $8,161
57 Added 52.78%
165 $90,000
Q4 2020

Feb 11, 2021

SELL
$78.0 - $104.5 $936 - $1,254
-12 Reduced 10.0%
108 $40,000
Q3 2020

Nov 12, 2020

BUY
$95.51 - $112.95 $1,910 - $2,259
20 Added 20.0%
120 $49,000
Q1 2020

May 14, 2020

BUY
$47.79 - $75.63 $4,779 - $7,563
100 New
100 $27,000

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $28.1B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track Clearstead Advisors, LLC Portfolio

Follow Clearstead Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clearstead Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clearstead Advisors, LLC with notifications on news.